“rational pharmacology” and health economics by alan maynard
TRANSCRIPT
![Page 1: “Rational Pharmacology” and Health Economics By Alan Maynard](https://reader036.vdocuments.net/reader036/viewer/2022082712/56649cc45503460f9498cff2/html5/thumbnails/1.jpg)
“Rational Pharmacology” and Health Economics
ByAlan Maynard
![Page 2: “Rational Pharmacology” and Health Economics By Alan Maynard](https://reader036.vdocuments.net/reader036/viewer/2022082712/56649cc45503460f9498cff2/html5/thumbnails/2.jpg)
Outline What is “rational pharmacology”? What is health economics? Is it time for marriage between
these two disciplines?! Developing the “fourth hurdle”
Conclusions
![Page 3: “Rational Pharmacology” and Health Economics By Alan Maynard](https://reader036.vdocuments.net/reader036/viewer/2022082712/56649cc45503460f9498cff2/html5/thumbnails/3.jpg)
Introductory comments “Doctors prescribe medicines of which
they know little, to cure diseases of which they know less, for human beings of whom they know nothing” Voltaire
Doctors are dangerous because practitioners exhibit large ,unexplained variations in practice, deliver inappropriate care and fail to manage medical errors or measure outcomes The role of pharmacologists and economists is to offer these sinners salvation!
![Page 4: “Rational Pharmacology” and Health Economics By Alan Maynard](https://reader036.vdocuments.net/reader036/viewer/2022082712/56649cc45503460f9498cff2/html5/thumbnails/4.jpg)
What is “rational pharmacology” 1? The role of the pharmacologist is to
identify the effects of drugs on the human body.
The measurement of safety, quality and efficacy
Problems with clinical trails : the choice of comparator and the scope for the scope for being ”economical with the truth”. The need for comparative efficacy data and the need to analyse products after marketing
![Page 5: “Rational Pharmacology” and Health Economics By Alan Maynard](https://reader036.vdocuments.net/reader036/viewer/2022082712/56649cc45503460f9498cff2/html5/thumbnails/5.jpg)
Rational Pharmacology 2 Identification of efficacy in trials and
effectiveness of drugs in the community are only the first two steps in deciding whether to reimburse a product in a health care system
Efficacy and effectiveness are necessary but not sufficient conditions for reimbursement e.g. if drug X produces 5 years of good quality life (5 QALYs) and drug Y produces 10 QALYs, which would you choose?
![Page 6: “Rational Pharmacology” and Health Economics By Alan Maynard](https://reader036.vdocuments.net/reader036/viewer/2022082712/56649cc45503460f9498cff2/html5/thumbnails/6.jpg)
Rational pharmacology 3 With such data about X and Y drugs, 1. The pharmacologist2. The physician3. The patient Would all prefer Y But what if drug X cost $50 and
drug Y cost $500? Which is the best buy now?
![Page 7: “Rational Pharmacology” and Health Economics By Alan Maynard](https://reader036.vdocuments.net/reader036/viewer/2022082712/56649cc45503460f9498cff2/html5/thumbnails/7.jpg)
Health economics 1 A basic assumption in economics is that
resources always and everywhere are scarce, and all decisions makers whether they are individuals or health care systems have to choose how to allocate scarce resources amongst competing ends
Health care rationing is ubiquitous and practitioners deprive (or simply do not offer) patients of care which is of benefit to them and which they would like to have.
![Page 8: “Rational Pharmacology” and Health Economics By Alan Maynard](https://reader036.vdocuments.net/reader036/viewer/2022082712/56649cc45503460f9498cff2/html5/thumbnails/8.jpg)
Health economics 2 The policy issue is not WHETHER to ration
but HOW access to care will be determined The individual (Hippocratic) ethic versus
the social (opportunity cost) ethic: doing good to the patient in your care versus recognising the need to target heath care to those patients who can benefit most per unit of expenditure
Evidence based medicine (EBM) versus economics based medicine (the new EBM!)
![Page 9: “Rational Pharmacology” and Health Economics By Alan Maynard](https://reader036.vdocuments.net/reader036/viewer/2022082712/56649cc45503460f9498cff2/html5/thumbnails/9.jpg)
Health economics 3 If drug X produces 5 QALYs for $50 and drug
Y produces 10 QALY for $500, the cost per QALY of X is $10, and the cost per QALY of Y is $50. Y produces 5 more QALYs at an additional cost of $450 or $90 per QALY
So Y is more clinically effective whilst X is cost effective. Some products which are clinically effective may also be cost effective. It is essential to identify, measure and value the costs and effects of all pharmaceutical products to determine cost effectiveness
![Page 10: “Rational Pharmacology” and Health Economics By Alan Maynard](https://reader036.vdocuments.net/reader036/viewer/2022082712/56649cc45503460f9498cff2/html5/thumbnails/10.jpg)
Health economics 4 If the available budget for a therapeutic
area is $100,00, product X produces 10,000 QALYs whilst product Y produces only 2000 QALYs. If the policy goal is to maximise population health gains, X must be used.
Thus the message is, depending on the cost and effectiveness data, what is clinically effective may not always be cost effective, but what is cost effective is always clinically effective.
![Page 11: “Rational Pharmacology” and Health Economics By Alan Maynard](https://reader036.vdocuments.net/reader036/viewer/2022082712/56649cc45503460f9498cff2/html5/thumbnails/11.jpg)
Health economics 5 Pharmacology and health economics are
partners in identifying, measuring and valuing what is given up when a patient uses a drug (the cost) and what is gained for the patient (improved length and quality of life)
In addition to the 3 “hurdles” of safety, efficacy and quality which have to be met to get marketing agreement, reimbursement has to be determined by the 4th hurdle of cost effectiveness e.g England and Australia
![Page 12: “Rational Pharmacology” and Health Economics By Alan Maynard](https://reader036.vdocuments.net/reader036/viewer/2022082712/56649cc45503460f9498cff2/html5/thumbnails/12.jpg)
Health economics 6:outline criteria for good study Clear definition of the hypothesis,
and the comparator. Identify, measure and value
relevant costs Identify measure and value all
relevant benefits Discount costs and benefits, and
carry out sensitivity analysis.
![Page 13: “Rational Pharmacology” and Health Economics By Alan Maynard](https://reader036.vdocuments.net/reader036/viewer/2022082712/56649cc45503460f9498cff2/html5/thumbnails/13.jpg)
Health economics 7 Many poor studies are published and used
for marketing by the industry Data basis of critiqued studies at NHS
Centre for reviews and Dissemination : www.york.ac.uk/inst/crd/centre.htm
Need to reappraise cost effectiveness continually with post marketing surveillance
Challenge to improve quality of studies and avoid corruption of the evidence base in both clinical and economic work
![Page 14: “Rational Pharmacology” and Health Economics By Alan Maynard](https://reader036.vdocuments.net/reader036/viewer/2022082712/56649cc45503460f9498cff2/html5/thumbnails/14.jpg)
Conclusions 1 Efficient reimbursement should be
informed by clinical and economic data Issues with the Fourth Hurdle (BMJ
360,576,2002):1. Where to set the “advisory cut off”: is
£30,000 per QALY too high?2. Prioritising the technologies for evaluation3. Political interference e.g beta interferon4. Guidance can be inflationary even if
efficient when the science is high quality
![Page 15: “Rational Pharmacology” and Health Economics By Alan Maynard](https://reader036.vdocuments.net/reader036/viewer/2022082712/56649cc45503460f9498cff2/html5/thumbnails/15.jpg)
Conclusions 2 “the role of the doctor is to amuse the
patient as nature takes its course” Voltaire
The determination of pharmaceutical formulae for primary and hospital care is a matter of science for clinical scientists, statisticians, pharmacologists and economists. The challenge then is to ensure that physicians follow guidelines based on the 4th hurdle.